Michael J. Johnston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael J. Johnston has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Ana Nikolic
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada
11 shared publicationsDonna L. Senger
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada
11 shared publicationsJennifer A. Chan
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
11 shared publicationsKatrina Ellestad
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada
11 shared publicationsAaron H. Gillmor
10 shared publicationsAdam C. Resnick
10 shared publications
Latest Publications
- Open Access
- 27 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma
Self-renewal is a crucial property of glioblastoma cells that is enabled by the choreographed functions of chromatin regulators and transcription factors. Identifying targetable epigenetic mechanisms of self-renewal could therefore represent an important step toward developing effective treatments for this universally lethal cancer. Here we uncover an epigenetic axis of self-renewal mediated by the histone variant macroH2A2. With omics and functional assays deploying patient-derived in vitro and in vivo models, we show that macroH2A2 shapes chromatin accessibility at enhancer elements to antagonize transcriptional programs of self-renewal. macroH2A2 also sensitizes cells to small molecule-mediated cell death via activation of a viral mimicry response. Consistent with these results, our analyses of clinical cohorts indicate that high transcriptional levels of this histone variant are associated with better prognosis of high-grade glioma patients. Our results reveal a targetable epigenetic mechanism of self-renewal controlled by macroH2A2 and suggest additional treatment approaches for glioblastoma patients.
- 27 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-22
Open AccessmacroH2A2 antagonizes epigenetic programs of stemness in glioblastoma
Self-renewal is a crucial property of glioblastoma cells that is enabled by the choreographed functions of chromatin regulators and transcription factors. Identifying targetable epigenetic mechanisms of self-renewal could therefore represent an important step toward developing effective treatments for this universally lethal cancer. Here we uncover an epigenetic axis of self-renewal mediated by the histone variant macroH2A2. With omics and functional assays deploying patient-derived in vitro and in vivo models, we show that macroH2A2 shapes chromatin accessibility at enhancer elements to antagonize transcriptional programs of self-renewal. macroH2A2 also sensitizes cells to small molecule-mediated cell death via activation of a viral mimicry response. Consistent with these results, our analyses of clinical cohorts indicate that high transcriptional levels of this histone variant are associated with better prognosis of high-grade glioma patients. Our results reveal a targetable epigenetic mechanism of self-renewal controlled by macroH2A2 and suggest additional treatment approaches for glioblastoma patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Data from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Supplemental Figures S1-S7, Supplemental Tables S1-S7. Methods and Figures S1-S8; Tables S1-S7. SF1: Heterozygous TP53 deletion in the germline and tumor of patient 1 and expression timelines of DSE. SF2: Mutational signatures in pGBM samples. SF3: Deletions at immune-modulatory loci and their effect on gene expression. SF4: Dynamics of germlines SVs during tumor evolution. SF5: Copy number assays using TaqMan probes confirm the deletion at the ATRX locus. SF6: Genetic heterogeneity at the ATRX locus. SF7: Distribution of allelic frequencies and clonal sizes in pGBM samples. ST1: Calgary pediatric GBM cohort. ST2: Therapeutic approach taken for each pediatric GBM patient in the Calgary cohort. ST3: Toronto pediatric GBM cohort used for WGS with linked reads and bulk RNA-seq. ST4: Features of each sample analyzed by whole-genome sequencing with linked reads. ST5: Genes mutated in diagnostic pGBM samples in more than one patient. ST6: Genes mutated in follow-up resections in more than one patient. ST7: Results of the fits of the first incomplete moment and the negative binomial like distribution to the samples.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Data from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Supplemental Figures S1-S7, Supplemental Tables S1-S7. Methods and Figures S1-S8; Tables S1-S7. SF1: Heterozygous TP53 deletion in the germline and tumor of patient 1 and expression timelines of DSE. SF2: Mutational signatures in pGBM samples. SF3: Deletions at immune-modulatory loci and their effect on gene expression. SF4: Dynamics of germlines SVs during tumor evolution. SF5: Copy number assays using TaqMan probes confirm the deletion at the ATRX locus. SF6: Genetic heterogeneity at the ATRX locus. SF7: Distribution of allelic frequencies and clonal sizes in pGBM samples. ST1: Calgary pediatric GBM cohort. ST2: Therapeutic approach taken for each pediatric GBM patient in the Calgary cohort. ST3: Toronto pediatric GBM cohort used for WGS with linked reads and bulk RNA-seq. ST4: Features of each sample analyzed by whole-genome sequencing with linked reads. ST5: Genes mutated in diagnostic pGBM samples in more than one patient. ST6: Genes mutated in follow-up resections in more than one patient. ST7: Results of the fits of the first incomplete moment and the negative binomial like distribution to the samples.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of single nucleotide variants.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of single nucleotide variants.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of single nucleotide variants.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of single nucleotide variants.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 3 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of somatic and de novo germline events.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 3 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of somatic and de novo germline events.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary File 3 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of somatic and de novo germline events.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 3 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Summary of somatic and de novo germline events.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Pediatric glioblastoma (pGBM) is a lethal cancer with no effective therapies. To understand the mechanisms of tumor evolution in this cancer, we performed whole-genome sequencing with linked reads on longitudinally resected pGBM samples. Our analyses showed that all diagnostic and recurrent samples were collections of genetically diverse subclones. Clonal composition rapidly evolved at recurrence, with less than 8% of nonsynonymous single-nucleotide variants being shared in diagnostic-recurrent pairs. To track the origins of the mutational events observed in pGBM, we generated whole-genome datasets for two patients and their parents. These trios showed that genetic variants could be (i) somatic, (ii) inherited from a healthy parent, or (iii) de novo in the germlines of pGBM patients. Analysis of variant allele frequencies supported a model of tumor growth involving slow-cycling cancer stem cells that give rise to fast-proliferating progenitor-like cells and to nondividing cells. Interestingly, radiation and antimitotic chemotherapeutics did not increase overall tumor burden upon recurrence. These findings support an important role for slow-cycling stem cell populations in contributing to recurrences, because slow-cycling cell populations are expected to be less prone to genotoxic stress induced by these treatments and therefore would accumulate few mutations. Our results highlight the need for new targeted treatments that account for the complex functional hierarchies and genomic heterogeneity of pGBM.Significance:This work challenges several assumptions regarding the genetic organization of pediatric GBM and highlights mutagenic programs that start during early prenatal development.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Pediatric glioblastoma (pGBM) is a lethal cancer with no effective therapies. To understand the mechanisms of tumor evolution in this cancer, we performed whole-genome sequencing with linked reads on longitudinally resected pGBM samples. Our analyses showed that all diagnostic and recurrent samples were collections of genetically diverse subclones. Clonal composition rapidly evolved at recurrence, with less than 8% of nonsynonymous single-nucleotide variants being shared in diagnostic-recurrent pairs. To track the origins of the mutational events observed in pGBM, we generated whole-genome datasets for two patients and their parents. These trios showed that genetic variants could be (i) somatic, (ii) inherited from a healthy parent, or (iii) de novo in the germlines of pGBM patients. Analysis of variant allele frequencies supported a model of tumor growth involving slow-cycling cancer stem cells that give rise to fast-proliferating progenitor-like cells and to nondividing cells. Interestingly, radiation and antimitotic chemotherapeutics did not increase overall tumor burden upon recurrence. These findings support an important role for slow-cycling stem cell populations in contributing to recurrences, because slow-cycling cell populations are expected to be less prone to genotoxic stress induced by these treatments and therefore would accumulate few mutations. Our results highlight the need for new targeted treatments that account for the complex functional hierarchies and genomic heterogeneity of pGBM.Significance:This work challenges several assumptions regarding the genetic organization of pediatric GBM and highlights mutagenic programs that start during early prenatal development.